| Year |
Citation |
Score |
| 2002 |
Bertrand L, Parent S, Caron M, Legault M, Joly E, Angers S, Bouvier M, Brown M, Houle B, Ménard L. The BRET2/arrestin assay in stable recombinant cells: a platform to screen for compounds that interact with G protein-coupled receptors (GPCRS). Journal of Receptor and Signal Transduction Research. 22: 533-41. PMID 12503639 DOI: 10.1081/Rrs-120014619 |
0.703 |
|
| 2001 |
Azzi M, Piñeyro G, Pontier S, Parent S, Ansanay H, Bouvier M. Allosteric effects of G protein overexpression on the binding of beta-adrenergic ligands with distinct inverse efficacies. Molecular Pharmacology. 60: 999-1007. PMID 11641428 DOI: 10.1124/Mol.60.5.999 |
0.373 |
|
| 1995 |
Valiquette M, Parent S, Loisel TP, Bouvier M. Mutation of tyrosine-141 inhibits insulin-promoted tyrosine phosphorylation and increased responsiveness of the human beta 2-adrenergic receptor. The Embo Journal. 14: 5542-9. PMID 8521811 DOI: 10.1002/J.1460-2075.1995.Tb00241.X |
0.568 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2013 |
Caruso ME, Clément P, Parent S, Dupriez V, Bossé R, Rouleau N. Integrated cell-based platform to study EGFR activation and transactivation. Assay and Drug Development Technologies. 11: 423-34. PMID 25310844 DOI: 10.1089/adt.2013.518 |
0.257 |
|
| 2020 |
Couëtoux du Tertre M, Marques M, McNamara S, Gambaro K, Hoffert C, Tremblay L, Bouchard N, Diaconescu R, Blais N, Couture C, Pelsser V, Wang H, McIntosh L, Hindie V, Parent S, et al. Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition. Clinical Proteomics. 17: 5. PMID 32055239 DOI: 10.1186/S12014-020-9269-6 |
0.168 |
|
| 2010 |
Bouchecareilh M, Caruso ME, Roby P, Parent S, Rouleau N, Taouji S, Pluquet O, Bossé R, Moenner M, Chevet E. AlphaScreen-based characterization of the bifunctional kinase/RNase IRE1alpha: a novel and atypical drug target. Journal of Biomolecular Screening. 15: 406-17. PMID 20237204 DOI: 10.1177/1087057110363823 |
0.119 |
|
| 2013 |
Brinkmalm G, Brinkmalm A, Bourgeois P, Persson R, Hansson O, Portelius E, Mercken M, Andreasson U, Parent S, Lipari F, Ohrfelt A, Bjerke M, Minthon L, Zetterberg H, Blennow K, et al. Soluble amyloid precursor protein α and β in CSF in Alzheimer's disease. Brain Research. 1513: 117-26. PMID 23541617 DOI: 10.1016/j.brainres.2013.03.019 |
0.106 |
|
| 2013 |
Nutu M, Bourgeois P, Zetterberg H, Portelius E, Andreasson U, Parent S, Lipari F, Hall S, Constantinescu R, Hansson O, Blennow K. Aβ1-15/16 as a potential diagnostic marker in neurodegenerative diseases. Neuromolecular Medicine. 15: 169-79. PMID 23225274 DOI: 10.1007/s12017-012-8208-8 |
0.097 |
|
| 2023 |
Tran JC, Hunsaker T, Bell C, Ma TP, Chan E, Larrocha PS, Homyk K, Liu L, La H, Mao J, de la Cruz CC, Yu K, Beresini M, Forrest WF, Xiao Y, ... ... Parent S, et al. Quantifying KRAS G12C Covalent Drug Inhibitor Activity in Mouse Tumors Using Mass Spectrometry. Analytical Chemistry. PMID 36876898 DOI: 10.1021/acs.analchem.2c04417 |
0.095 |
|
| 2008 |
Beaudet L, Rodriguez-Suarez R, Venne M, Caron M, Bédard J, Brechler V, Parent S, Bielefeld-Sévigny M. AlphaLISA immunoassays: the no-wash alternative to ELISAs for research and drug discovery Nature Methods. 5: an8-an9. DOI: 10.1038/NMETH.F.230 |
0.036 |
|
| 2012 |
Nutu M, Bourgeois P, Zetterberg H, Portelius E, Lipari F, Parent S, Hansson O, Blennow K. P1-022: The use of AlphaLISA in measurement of Aβ1-15/16 as a potential biomarker in neurodegenerative diseases Alzheimer's & Dementia. 8: P115-P115. DOI: 10.1016/j.jalz.2012.05.297 |
0.025 |
|
| Hide low-probability matches. |